Sign In
Buy BLRX
$3.39
-0.0900 (-2.59%)
At Close: Jun 02, 2026
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
07:00am, Tuesday, 18'th Nov 2025
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd.
Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-expressed (representing over 90% of cancers) Patent further broadens and strengthens GLIX1 patent pro
BioLineRx Ltd. - Special Call
03:27pm, Monday, 29'th Sep 2025
BioLineRx Ltd. - Special Call Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Ella Sorani - Chief Development Officer Conference Call Participants Joseph
- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 - - Gliobl
BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript
10:44am, Thursday, 14'th Aug 2025
BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Irina Koffler - Corporate Participant Mali Zeevi - Chief Financial Officer Philip A.
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Thursday, 14'th Aug 2025
- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- Provides updated and extended cash
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
07:00am, Thursday, 07'th Aug 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2025 /PRNewswire/ -- BioLineRx Ltd.
3 Stocks Getting Rare Double Upgrades From Analysts
02:30pm, Friday, 06'th Jun 2025
Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts' expectations.
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
01:58pm, Friday, 30'th May 2025
BioLineRx Ltd's BLRX poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 Am
BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript
12:55pm, Tuesday, 27'th May 2025
BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2025 Earnings Conference Call May 27, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Philip Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chie
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Tuesday, 27'th May 2025
- Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot phase of ongoing CheMo4METPANC Pha
BioLineRx to Report First Quarter 2025 Results on May 27, 2025
07:00am, Tuesday, 20'th May 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 20, 2025 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript
10:52am, Monday, 31'st Mar 2025
BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chie
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
07:00am, Monday, 31'st Mar 2025
- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. f
BioLineRx to Report 2024 Annual Results on March 31, 2025
07:00am, Monday, 24'th Mar 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 /PRNewswire/ -- BioLineRx Ltd.
